<br />
VOL. 22 SUPPL. 1 A SUPPLEMENT TO www.clinicianreviews.com<br />
Optimizing Patient Outcomes in<br />
Diabetes Management<br />
■ Individualizing Diabetes Therapy<br />
■ Challenges of Adherence: Room<br />
for Improvement<br />
■ Managing Hypoglycemia<br />
■ Advances in Diabetes Therapies<br />
This supplement is<br />
supported by funding<br />
from Novo Nordisk Inc.<br />
A Supplement to<br />
www.clinicianreviews.com<br />
A Supplement to<br />
PUBLISHING<br />
Executive VP, QHI, President, Primary Care Group<br />
JoAnn Wahl<br />
(973) 206-8989<br />
E-mail: joann.wahl@qhc.com<br />
Group Publisher<br />
Christy Tetterton<br />
(973) 206-8984<br />
E-mail: christy.tetterton@qhc.com<br />
National Account Manager<br />
Steve Farrell<br />
(973) 206-2322<br />
E-mail: steve.farrell@qhc.com<br />
Senior Account Manager/Advertising Sales<br />
K<a title="CR NovoNordisk Digital Edition page 1" href="http://viewer.zmags.com/publication/fd4fd239?page=1"> VOL. 22 SUPPL. 1 </a>
<a title="CR NovoNordisk Digital Edition page 2" href="http://viewer.zmags.com/publication/fd4fd239?page=2"> A Supplement to www.clinicianreviews.com</a>
<a title="CR NovoNordisk Digital Edition page 3" href="http://viewer.zmags.com/publication/fd4fd239?page=3"> A Supplement to PUBLISHING Executive VP,</a>
<a title="CR NovoNordisk Digital Edition page 4" href="http://viewer.zmags.com/publication/fd4fd239?page=4"> Introduction The Role of the PA/NP in Diabetes </a>
<a title="CR NovoNordisk Digital Edition page 5" href="http://viewer.zmags.com/publication/fd4fd239?page=5"> need for new treatment options for management of </a>
<a title="CR NovoNordisk Digital Edition page 6" href="http://viewer.zmags.com/publication/fd4fd239?page=6"> Individualizing Diabetes Therapy Scott Urquhart,</a>
<a title="CR NovoNordisk Digital Edition page 7" href="http://viewer.zmags.com/publication/fd4fd239?page=7"> in A1C levels. The risk for hypo- glycemia with T</a>
<a title="CR NovoNordisk Digital Edition page 8" href="http://viewer.zmags.com/publication/fd4fd239?page=8"> TABLE 2: Characteristics of Commonly Used Insulin</a>
<a title="CR NovoNordisk Digital Edition page 9" href="http://viewer.zmags.com/publication/fd4fd239?page=9"> its use with insulin has been associated with an </a>
<a title="CR NovoNordisk Digital Edition page 10" href="http://viewer.zmags.com/publication/fd4fd239?page=10"> A PA's Experience with Insulin: Pearls for Starti</a>
<a title="CR NovoNordisk Digital Edition page 11" href="http://viewer.zmags.com/publication/fd4fd239?page=11"> level of >7% for 10 years.9 This unnecessary dela</a>
<a title="CR NovoNordisk Digital Edition page 12" href="http://viewer.zmags.com/publication/fd4fd239?page=12"> Challenges of Adherence in Diabetes Care: Room fo</a>
<a title="CR NovoNordisk Digital Edition page 13" href="http://viewer.zmags.com/publication/fd4fd239?page=13"> problems and that many have poor psychological we</a>
<a title="CR NovoNordisk Digital Edition page 14" href="http://viewer.zmags.com/publication/fd4fd239?page=14"> </a>
<a title="CR NovoNordisk Digital Edition page 15" href="http://viewer.zmags.com/publication/fd4fd239?page=15"> Case Scenario: Strategies for Changing Patient Be</a>
<a title="CR NovoNordisk Digital Edition page 16" href="http://viewer.zmags.com/publication/fd4fd239?page=16"> through the stages of change and encouraged to st</a>
<a title="CR NovoNordisk Digital Edition page 17" href="http://viewer.zmags.com/publication/fd4fd239?page=17"> Managing Hypoglycemia in Patients with Type 2 Dia</a>
<a title="CR NovoNordisk Digital Edition page 18" href="http://viewer.zmags.com/publication/fd4fd239?page=18"> cometer readings and make adjustments based on th</a>
<a title="CR NovoNordisk Digital Edition page 19" href="http://viewer.zmags.com/publication/fd4fd239?page=19"> are at higher risk for drug-associated hypoglyce-</a>
<a title="CR NovoNordisk Digital Edition page 20" href="http://viewer.zmags.com/publication/fd4fd239?page=20"> derstanding will provide a sense of greater contr</a>
<a title="CR NovoNordisk Digital Edition page 21" href="http://viewer.zmags.com/publication/fd4fd239?page=21"> Advances in Diabetes Therapies Jeff Unger, MD </a>
<a title="CR NovoNordisk Digital Edition page 22" href="http://viewer.zmags.com/publication/fd4fd239?page=22"> receptor agonists and DPP-4 inhibitors, are effec</a>
<a title="CR NovoNordisk Digital Edition page 23" href="http://viewer.zmags.com/publication/fd4fd239?page=23"> the subcutaneous tissue. The insulin com- plex bo</a>
<a title="CR NovoNordisk Digital Edition page 24" href="http://viewer.zmags.com/publication/fd4fd239?page=24"> ited an 18% lower rate (P = .036) of overall conf</a>
<a title="CR NovoNordisk Digital Edition page 25" href="http://viewer.zmags.com/publication/fd4fd239?page=25"> AstraZeneca) to provide additional data in regard</a>
<a title="CR NovoNordisk Digital Edition page 26" href="http://viewer.zmags.com/publication/fd4fd239?page=26"> daily, and 1049 patients were given placebo. The </a>
<a title="CR NovoNordisk Digital Edition page 27" href="http://viewer.zmags.com/publication/fd4fd239?page=27"> 22. Ferrannini E, Ramos SJ, Salsali A, et al. Dap</a>
<a title="CR NovoNordisk Digital Edition page 28" href="http://viewer.zmags.com/publication/fd4fd239?page=28"> </a>